Respiratory infection is very common in patients suffering from cystic fibrosis (CF). However, the antimicrobial resistance rate of isolates from CF patients is not often documented. In this study, 279 respiratory specimens of 146 “patients” were prospectively collected from July to December 2006. Microbiological cultures and antimicrobial susceptibility tests of the most frequently isolated bacteria were performed. Sputum and oropharyngeal swabs were processed for culture. During the study period, 50% of the patients harbored Staphylococcus aureus, 35% Pseudomonas aeruginosa, 4.7% Haemophilus influenzae. Methicillin resistant S. aureus (MRSA) were detected in 8 (6%) patients; ESBL and MBL-producing P. aeruginosa were not identified in these patients. The detection of MRSA in CF patients confirms that antimicrobial resistance patterns should be always kept under surveillance. Moreover, hygiene regulations in CF clinics should prevent a further spread of resistant bacterial strains.
Journal Information
Vol. 14. Issue 4.
Pages 406-409 (July - August 2010)
Vol. 14. Issue 4.
Pages 406-409 (July - August 2010)
Brief communication
Open Access
Prevalence and antimicrobial susceptibility of respiratory pathogens in patients with cystic fibrosis
Visits
2750
Vilma Almeida Paixão1,2,
, Tânia Fraga Barros2, Clélia Maria C. Mota1,2, Tamy Fagundes Moreira2, Maria Angélica Santana1, Joice Neves Reis2
Corresponding author
vvilmapaixao@gmail.com
Correspondence to: Rua das Gaivotas, no. 128 BL-C, Apto 1503, Imbuí, Salvador – Bahia – Brazil. CEP: 41720-070. Tel.: +55-71-32312078; fax: +55-71-32372255.
Correspondence to: Rua das Gaivotas, no. 128 BL-C, Apto 1503, Imbuí, Salvador – Bahia – Brazil. CEP: 41720-070. Tel.: +55-71-32312078; fax: +55-71-32372255.
This item has received
Article information
Abstract
Keywords:
cystic fibrosis
antimicrobial resistance
Pseudomonas aeruginosa
Staphylococcus aureus
Full text is only aviable in PDF
References
[1.]
F.A. Ratjen.
Cystic fibrosis: pathogenesis and future treatment strategies.
Respir Care, 54 (2009), pp. 595-605
[2.]
R.C. Boucher.
New concepts of the pathogenesis of cystic fibrosis lung disease.
Eur Respir J, 23 (2004), pp. 146-158
[3.]
L. Saiman, J. Siegel.
Infection control in cystic fibrosis.
Clin Microbiol Rev, 17 (2004), pp. 57-71
[4.]
S. Rajan, L. Saiman.
Pulmonary infections in patients with cystic fibrosis.
Semin Respir Infect, 17 (2002), pp. 47-56
[5.]
B.P. O'Sullivan, S.D. Freedman.
Cystic fibrosis.
Lancet, 373 (2009), pp. 1891-1904
[6.]
B.J. Rosenstein, G.R. Cutting.
The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel.
J Pediatr, 132 (1998), pp. 589-595
[7.]
CLSI. Performance standards for antimicrobial susceptibility testing, in Seventeenth Informational Supplement. 2007, Approved Standard M100-S17: Wayne, PA.
[8.]
A. Lambiase, V. Raia, M. Del Pezzo, A. Sepe, V. Carnovale, F. Rossano.
Microbiology of airway disease in a cohort of patients with cystic fibrosis.
BMC Infect Dis, 6 (2006), pp. 4
[9.]
G. Valenza, D. Tappe, D. Turnwald, et al.
Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis.
J Cyst Fibros, 7 (2008), pp. 123-127
[10.]
M.A. Santana, E. Matos, M. do Socorro Fontoura, R. Franco, D. Barreto, A.C. Lemos.
Prevalence of pathogens incystic fibrosis patients in Bahia.
Brazil. Braz J Infect Dis, 7 (2003), pp. 69-72
[11.]
M.M. Anzaudo, N.P. Busquets, S. Ronchi, C. Mayoral.
Isolated pathogen microorganisms in respiratory samples from children with cystic fibrosis.
Rev Argent Microbiol, 37 (2005), pp. 129-134
[12.]
A.D. García, A. Ibarra, F.C. Rodríguez, M. Casal.
Antimicrobial susceptibility of bacterial isolates from patients with cystic fibrosis.
Rev Esp Quimioter, 17 (2004), pp. 332-335
[13.]
S. Razvi, L. Quittell, A. Sewal, H. Quinton, B. Marshall, L. Saiman.
Respiratory microbiology of patients with cystic fibrosis in the United States, 1995-2005.
Chest, (2009),
[14.]
J.L. Burns, J. Emerson, J.R. Stapp, et al.
Microbiology of sputum from patients at cystic fibrosis centers in the United States.
Clin Infect Dis, 27 (1998), pp. 158-163
[15.]
H. Nishio, M. Komatsu, N. Shibata, et al.
Metallo-beta-lactamase- producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the Kinki region of Japan.
J Clin Microbiol, 42 (2004), pp. 5256-5263
[16.]
L. Lauretti, M.L. Riccio, A. Mazzarol, et al.
Cloning and characterization of blaVIM, a new integron-borne metallo-betalactamase gene from a Pseudomonas aeruginosa clinical isolate.
Antimicrob Agents Chemother, 43 (1999), pp. 1584-1590
[17.]
A.C. Gales, L.C. Menezes, S. Silbert, H.S. Sader.
Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-betalactamase.
J Antimicrob Chemother, 52 (2003), pp. 699-702
[18.]
A.C. Gales, L.C. Menezes, S. Silbert, H.S. Sader.
Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-betalactamase.
J Antimicrob Chemother, 52 (2003), pp. 699-702
[19.]
P.S. Stewart, J. Rayner, F. Roe, W.M. Rees.
Biofilm penetration and disinfection efficacy of alkaline hypochlorite and chlorosulfamates.
J Appl Microbiol, 91 (2001), pp. 525-532
[20.]
S.D. Aaron, K. Ramotar, W. Ferris, et al.
Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa.
Am J Respir Crit Care Med, 169 (2004), pp. 811-815
Copyright © 2010. Elsevier Editora Ltda.. All rights reserved